These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Targeted measles virus vector displaying echistatin infects endothelial cells via alpha(v)beta3 and leads to tumor regression. Hallak LK; Merchan JR; Storgard CM; Loftus JC; Russell SJ Cancer Res; 2005 Jun; 65(12):5292-300. PubMed ID: 15958576 [TBL] [Abstract][Full Text] [Related]
7. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Grote D; Russell SJ; Cornu TI; Cattaneo R; Vile R; Poland GA; Fielding AK Blood; 2001 Jun; 97(12):3746-54. PubMed ID: 11389012 [TBL] [Abstract][Full Text] [Related]
8. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Peng KW; TenEyck CJ; Galanis E; Kalli KR; Hartmann LC; Russell SJ Cancer Res; 2002 Aug; 62(16):4656-62. PubMed ID: 12183422 [TBL] [Abstract][Full Text] [Related]
9. Engineered measles virus as a novel oncolytic therapy against prostate cancer. Msaouel P; Iankov ID; Allen C; Morris JC; von Messling V; Cattaneo R; Koutsilieris M; Russell SJ; Galanis E Prostate; 2009 Jan; 69(1):82-91. PubMed ID: 18973133 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Ong HT; Hasegawa K; Dietz AB; Russell SJ; Peng KW Gene Ther; 2007 Feb; 14(4):324-33. PubMed ID: 17051248 [TBL] [Abstract][Full Text] [Related]
14. Enhanced antitumor effects of an engineered measles virus Edmonston strain expressing the wild-type N, P, L genes on human renal cell carcinoma. Meng X; Nakamura T; Okazaki T; Inoue H; Takahashi A; Miyamoto S; Sakaguchi G; Eto M; Naito S; Takeda M; Yanagi Y; Tani K Mol Ther; 2010 Mar; 18(3):544-51. PubMed ID: 20051938 [TBL] [Abstract][Full Text] [Related]
16. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Phuong LK; Allen C; Peng KW; Giannini C; Greiner S; TenEyck CJ; Mishra PK; Macura SI; Russell SJ; Galanis EC Cancer Res; 2003 May; 63(10):2462-9. PubMed ID: 12750267 [TBL] [Abstract][Full Text] [Related]
17. A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. McDonald CJ; Erlichman C; Ingle JN; Rosales GA; Allen C; Greiner SM; Harvey ME; Zollman PJ; Russell SJ; Galanis E Breast Cancer Res Treat; 2006 Sep; 99(2):177-84. PubMed ID: 16642271 [TBL] [Abstract][Full Text] [Related]
18. Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma. Peng KW; Dogan A; Vrana J; Liu C; Ong HT; Kumar S; Dispenzieri A; Dietz AB; Russell SJ Am J Hematol; 2009 Jul; 84(7):401-7. PubMed ID: 19507209 [TBL] [Abstract][Full Text] [Related]
19. Graphene oxide arms oncolytic measles virus for improved effectiveness of cancer therapy. Xia M; Luo D; Dong J; Zheng M; Meng G; Wu J; Wei J J Exp Clin Cancer Res; 2019 Sep; 38(1):408. PubMed ID: 31533779 [TBL] [Abstract][Full Text] [Related]
20. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Anderson BD; Nakamura T; Russell SJ; Peng KW Cancer Res; 2004 Jul; 64(14):4919-26. PubMed ID: 15256464 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]